DOCSLIB.ORG

Distinct Patterns of Somatic Genome Alterations in Lung

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Distinct Patterns of Somatic Genome Alterations in Lung ARTICLES Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas Joshua D Campbell1,2, Anton Alexandrov3,4, Jaegil Kim1, Jeremiah Wala1,2, Alice H Berger1,2, Chandra Sekhar Pedamallu1,2, Sachet A Shukla1,2, Guangwu Guo1,2, Angela N Brooks1,2, Bradley A Murray1,2, Marcin Imielinski1,2,5, Xin Hu6, Shiyun Ling6, Rehan Akbani6, Mara Rosenberg1, Carrie Cibulskis1, Aruna Ramachandran1,2, Eric A Collisson7, David J Kwiatkowski1,8, Michael S Lawrence1, John N Weinstein6, Roel G W Verhaak6, Catherine J Wu1,2, Peter S Hammerman1,2, Andrew D Cherniack1,2, Gad Getz1,9, Cancer Genome Atlas Research Network10, Maxim N Artyomov3, Robert Schreiber3, Ramaswamy Govindan11, Matthew Meyerson1,2,12 To compare lung adenocarcinoma (ADC) and lung squamous cell carcinoma (SqCC) and to identify new drivers of lung carcinogenesis, we examined the exome sequences and copy number profiles of 660 lung ADC and 484 lung SqCC tumor–normal pairs. Recurrent alterations in lung SqCCs were more similar to those of other squamous carcinomas than to alterations in lung ADCs. New significantly mutated genes included PPP3CA, DOT1L, and FTSJD1 in lung ADC, RASA1 in lung SqCC, and KLF5, EP300, and CREBBP in both tumor types. New amplification peaks encompassed MIR21 in lung ADC, MIR205 in lung SqCC, and MAPK1 in both. Lung ADCs lacking receptor tyrosine kinase–Ras–Raf pathway alterations had mutations in SOS1, VAV1, RASA1, and ARHGAP35. Regarding neoantigens, 47% of the lung ADC and 53% of the lung SqCC tumors had at least five predicted neoepitopes. Although targeted therapies for lung ADC and SqCC are largely distinct, immunotherapies may aid in treatment for both subtypes. Lung cancer remains the leading cause of death from cancer around genes can be challenging because of the large number of passenger the world1. An estimated 221,000 new cases and 158,000 deaths mutations that can accumulate from prolonged exposure to tobacco Nature America, Inc. All rights reserved. Inc. Nature America, from lung cancer occurred in the United States alone in 2015 (ref. 2). carcinogens and from inherent mutagenic processes such as aberrant 6 The two major histological classes are non-small-cell lung can- activity of APOBEC cytidine deaminases9. Profiling larger numbers cer (NSCLC) and small-cell lung cancer (SCLC). NSCLCs mostly of samples within a tumor type and combining samples across tumor © 201 comprise lung ADCs and lung SqCCs. These two NSCLC subtypes types can help overcome this problem, by providing the additional have both unique and shared clinical and histopathological charac- statistical power necessary to distinguish important genes mutated teristics. For example, whereas smoking is the major risk factor for at a lower frequency than other genes with passenger mutations10. In both subtypes, approximately 10–15% of lung ADCs are observed addition, a comprehensive comparison of recurrently altered genes in never-smokers3. Molecularly targeted therapies directed against found in lung ADC and lung SqCC has not been performed. Such receptor tyrosine kinases (RTKs) lead to dramatic responses in analyses may yield insights into the similarities and differences in subsets of patients with lung ADCs harboring activating genomic carcinogenesis between the diseases and elucidate the degree to which alterations in the corresponding kinase genes, including EGFR, ALK, common or distinct targeted and immunological therapeutic strate- and ROS1 (ref. 4). Other targeted therapies under current investi- gies can be used to treat each cancer type. gation are directed against activating alterations in the MET, RET, NTRK1, NTRK2, ERBB2, and BRAF kinases4,5. RESULTS Recent efforts have focused on comprehensively characterizing the Comparison of somatically altered genes changes found in the genome, epigenome, transcriptome, and pro- To compare the somatic profiles of lung ADC and lung SqCC and teome in lung ADCs and SqCCs to discover new cancer driver genes to identify new genetic alterations, we studied 660 lung ADC–nor- that may be clinically actionable6–8. Identifying new cancer-related mal paired exome sequences (including 274 previously unpublished 1Cancer Program, Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 3Department of Pathology and Immunology, Washington University, St. Louis, Missouri, USA. 4Computer Technologies Laboratory, ITMO University, St. Petersburg, Russia. 5Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, Massachusetts, USA. 6Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 7Department of Medicine, University of California, San Francisco, San Francisco, California, USA. 8Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA. 9Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA. 10A full list of members and affiliations appears at the end of the paper. 11Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. 12Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA. Correspondence should be addressed to M.M. ([email protected]) or R.G. ([email protected]). Received 4 September 2015; accepted 12 April 2016; published online 9 May 2016; doi:10.1038/ng.3564 NATURE GEnETICS ADVANCE ONLINE PUBLICATION 1 ARTICLES a Significantly mutated genes b Focal amplifications c Focal deletions TP53 NKX2−1 CDKN2A KRAS –64 –128 KEAP1 NF1 10 10 EGFR RB1 TERT –8 BRAF ARID1A –32 MYC –64 10 ERBB2 STK11 10 MCL1 10 SMARCA4 CDK4 MDM2 PTPRD SETD2 –32 RBM10 –16 KRAS 10 MGA 10 CCND1 MET EGFR –16 B2M alue alue alue –4 ATM CDKN2A MECOM–TERC 10 v –8 CCNE1 v v 10 U2AF1 WWOX LRP1B q 10 q PDE4D q RIT1 ERBB2 –8 WHSC1L1–FGFR1 10 10–4 SMAD4 RB1 ARID2 –4 SMAD4 MET 18q11.2 10 Xp22.2 –2 PDGFRA–KIT–KDR 21q21.1 CSMD1 10 CTNNB1 NFE2L2 10–2 Lung ADC –2 Lung ADC Lung ADC APC 10 4q22.1 PIK3CA PTEN RAF1 –1 6q22.31 MLL2 –1 ZMYND11 NRAS 10 CDK6 REL–BCL11A 10 MAP2K1 19p13.2 FOXP1 10–1 HRAS KDM6A NOTCH1 FAT1 MYCL1 BCL2L1 NFE2L2 SOX2 KDM6A NF1 FAT1 PTEN NS NS NS NS 10–1 10–2 10–4 10–8 NS 10–1 10–2 10–4 10–8 10–1610–3210–6410–128 NS 10–1 10–2 10–4 10–810–1610–3210–6410–128 Lung SqCC q value Lung SqCC q value Lung SqCC q value Figure 1 Distinct somatic alterations in lung ADC and lung SqCC. (a) The MutSig2CV algorithm10 was used to identify significantly mutated genes across 660 lung ADCs and 484 lung SqCCs. Genes with q values <0.1 were considered to be significantly mutated. The q value for each gene in the lung ADC cohort is plotted against the respective q value in the lung SqCC cohort. The majority of significantly mutated genes were unique to either tumor type. (b,c) The GISTIC 2.0 algorithm was used to identify significantly recurrent copy number gains and losses. The q values for amplifications (b) and deletions (c) in the lung ADC cohort are plotted against the respective q values in the lung SqCC cohort. Peaks with q values <0.25 were considered to be significant. Deletions located within putative fragile sites are highlighted with green labels. Only points corresponding to genes with a previously characterized role in lung cancer are labeled. NS, not significant. cases and 227 previously described cases from The Cancer Genome Mutational signatures in lung cancer Atlas (TCGA)6 together with 159 cases from the cohort in Imielinski Various carcinogenic and cancer-related processes contribute to the et al.8) and 484 lung SqCC–normal paired exome sequences (includ- mutational patterns observed in tumors13,14. Previous large-scale ing 308 previously unpublished cases and 176 previously described studies of lung cancer genomes have identified signatures associated cases from TCGA7; Supplementary Tables 1–4). Similarly to with non-smoking and smoking cases6,8,15; here we extend these previous studies6,7, we observed median somatic mutation rates findings through the improved statistical power of our larger sample of 8.7 mutations/Mb and 9.7 mutations/Mb for lung ADCs and set. Using non-negative matrix factorization (NMF)13,16 (Online SqCCs, respectively. After excluding genes with lower median Methods), we identified six mutational signatures in this cohort, many expression (log2 (FPKM) <6.16 for lung ADCs and <6.27 for lung of which are strongly correlated with previously defined signatures SqCCs; Online Methods and Supplementary Fig. 1), we identi- in the Catalogue of Somatic Mutations in Cancer (COSMIC) data- fied 38 genes as significantly mutated in lung ADC and 20 genes base13,17 (Supplementary Figs. 3–5 and Supplementary Table 7). as significantly mutated in lung SqCC using MutSig2CV10 (q value These included a UV-related signature of C>T changes at TCC or Nature America, Inc. All rights reserved. Inc. Nature America, < 0.1; Supplementary Tables 5 and 6). Only six genes—TP53, RB1, CCC sites (COSMIC signature 7, abbreviated SI7), a smoking-related 6 ARID1A, CDKN2A, PIK3CA, and NF1—were significantly mutated signature of C>A transversions (SI4), a mismatch-repair (MMR) in both tumor types, and, of these, TP53, CDKN2A, and PIK3CA signature of C>T changes at GCG sites (SI15/SI6), two APOBEC- © 201 had a significantly higher mutation frequency in lung SqCC tumors related signatures of C>G or C>T changes at TCT or TCA sites (P < 0.01, Fisher’s exact test; Fig. 1a). Likewise, only 11 of 42 focal (SI13 and SI2), and a final signature with a moderate correlation to amplification peaks were identified as altered in both tumor types COSMIC signature 5 (SI5) with putative ‘molecular clock’ properties18 (Fig. 1b), and 13 of 50 focal deletion peaks were altered in both (Supplementary Fig. 5). In addition to identifying mutational signa- tumor types (Fig.
Load more

Recommended publications
  • MECOM Permits Pancreatic Acinar Cell Dedifferentiation Avoiding Cell Death Under Stress Conditions
    Cell Death & Differentiation (2021) 28:2601–2615 https://doi.org/10.1038/s41418-021-00771-6 ARTICLE MECOM permits pancreatic acinar cell dedifferentiation avoiding cell death under stress conditions 1 2 2 1 1 1,3 Elyne Backx ● Elke Wauters ● Jonathan Baldan ● Mathias Van Bulck ● Ellis Michiels ● Yves Heremans ● 4 5 5 2 6 Diedert Luc De Paep ● Mineo Kurokawa ● Susumu Goyama ● Luc Bouwens ● Patrick Jacquemin ● 1,2 1 Isabelle Houbracken ● Ilse Rooman Received: 20 July 2020 / Revised: 3 March 2021 / Accepted: 4 March 2021 / Published online: 24 March 2021 © The Author(s) 2021. This article is published with open access Abstract Maintenance of the pancreatic acinar cell phenotype suppresses tumor formation. Hence, repetitive acute or chronic pancreatitis, stress conditions in which the acinar cells dedifferentiate, predispose for cancer formation in the pancreas. Dedifferentiated acinar cells acquire a large panel of duct cell-specific markers. However, it remains unclear to what extent dedifferentiated acini differ from native duct cells and which genes are uniquely regulating acinar cell dedifferentiation. Moreover, most studies have been performed on mice since the availability of human cells is scarce. Here, we applied a non- fi 1234567890();,: 1234567890();,: genetic lineage tracing method of human pancreatic exocrine acinar and duct cells that allowed cell-type-speci c gene expression profiling by RNA sequencing. Subsequent to this discovery analysis, one transcription factor that was unique for dedifferentiated acinar cells was functionally characterized. RNA sequencing analysis showed that human dedifferentiated acinar cells expressed genes in “Pathways of cancer” with a prominence of MECOM (EVI-1), a transcription factor that was not expressed by duct cells.
    [Show full text]
  • Prospective Isolation of NKX2-1–Expressing Human Lung Progenitors Derived from Pluripotent Stem Cells
    The Journal of Clinical Investigation RESEARCH ARTICLE Prospective isolation of NKX2-1–expressing human lung progenitors derived from pluripotent stem cells Finn Hawkins,1,2 Philipp Kramer,3 Anjali Jacob,1,2 Ian Driver,4 Dylan C. Thomas,1 Katherine B. McCauley,1,2 Nicholas Skvir,1 Ana M. Crane,3 Anita A. Kurmann,1,5 Anthony N. Hollenberg,5 Sinead Nguyen,1 Brandon G. Wong,6 Ahmad S. Khalil,6,7 Sarah X.L. Huang,3,8 Susan Guttentag,9 Jason R. Rock,4 John M. Shannon,10 Brian R. Davis,3 and Darrell N. Kotton1,2 2 1Center for Regenerative Medicine, and The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA. 3Center for Stem Cell and Regenerative Medicine, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas, USA. 4Department of Anatomy, UCSF, San Francisco, California, USA. 5Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA. 6Department of Biomedical Engineering and Biological Design Center, Boston University, Boston, Massachusetts, USA. 7Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA. 8Columbia Center for Translational Immunology & Columbia Center for Human Development, Columbia University Medical Center, New York, New York, USA. 9Department of Pediatrics, Monroe Carell Jr. Children’s Hospital, Vanderbilt University, Nashville, Tennessee, USA. 10Division of Pulmonary Biology, Cincinnati Children’s Hospital, Cincinnati, Ohio, USA. It has been postulated that during human fetal development, all cells of the lung epithelium derive from embryonic, endodermal, NK2 homeobox 1–expressing (NKX2-1+) precursor cells.
    [Show full text]
  • Genome-Wide CRISPR Screening Identifies BRD9 As a Druggable Component Of
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.04.429732; this version posted February 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Genome-Wide CRISPR Screening Identifies BRD9 as a Druggable Component of 2 Interferon-Stimulated Gene Expression and Antiviral Activity 3 Jacob Börolda,b,†, Davide Elettoa,†,#, Idoia Busnadiegoa, Nina K. Maira,b, Eva Moritza, 4 Samira Schiefera,b, Nora Schmidta,$, Philipp P. Petricc,d, W. Wei-Lynn Wonge, Martin 5 Schwemmlec & Benjamin G. Halea,* 6 7 aInstitute of Medical Virology, University of Zurich, Zurich, Switzerland. 8 bLife Science Zurich Graduate School, ETH and University of Zurich, Zurich, 9 Switzerland. 10 cInstitute of Virology, Freiburg University Medical Center, Faculty of Medicine, University 11 of Freiburg, Freiburg, Germany. 12 dSpemann Graduate School of Biology and Medicine, University of Freiburg, Freiburg, 13 Germany. 14 eInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland. 15 *Correspondence: Benjamin G. Hale, [email protected] 16 †Equal first authors listed in alphabetical order. 17 #Present address: Department of Biosystems Science and Engineering, ETH Zurich, 18 Basel, Switzerland. 19 $Present address: Helmholtz Institute for RNA-based Infection Research, Helmholtz- 20 Center for Infection Research, Wurzburg, Germany. 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.02.04.429732; this version posted February 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Increased ACTL6A Occupancy Within Mswi/SNF Chromatin Remodelers
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.22.435873; this version posted March 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Increased ACTL6A Occupancy Within mSWI/SNF Chromatin Remodelers Drives Human Squamous Cell Carcinoma Chiung-Ying Chang1,2,7, Zohar Shipony3,7, Ann Kuo1,2, Kyle M. Loh4,5, William J. Greenleaf3,6, Gerald R. Crabtree1,2,5* 1Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305, USA. 2Department of Pathology, Stanford University School of Medicine, Stanford, California 94305, USA. 3Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA. 4Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California 94305, USA. 5Department of Developmental Biology, Stanford University School of Medicine, Stanford, California 94305, USA. 6Department of Applied Physics, Stanford University, Stanford, California 94305, USA. 7These authors contributed equally. *Corresponding author: Gerald R. Crabtree, [email protected] Summary Mammalian SWI/SNF (BAF) chromatin remodelers play dosage-sensitive roles in many human malignancies and neurologic disorders. The gene encoding the BAF subunit, ACTL6A, is amplified at an early stage in the development of squamous cell carcinomas (SCCs), but its oncogenic role remains unclear. Here we demonstrate that ACTL6A overexpression leads to its stoichiometric assembly into BAF complexes and drives its interaction and engagement with specific regulatory regions in the genome. In normal epithelial cells, ACTL6A was sub-stoichiometric to other BAF subunits. However, increased ACTL6A levels by ectopic expression or in SCC cells led to near-saturation of ACTL6A within BAF complexes.
    [Show full text]
  • Factsheet XL T3;3 GATA2MECOM DF D-5124.Cdt
    XL t(3;3) GATA2/ MECOM DF Translocation/Dual Fusion Order No.: Probe D-5124-100-OG Description XL t(3;3) GATA2/MECOM DF is designed as a dual fusion probe. The orange labeled probe spans the breakpoint at 3q26 (MECOM), the green labeled probe spans the breakpoint at 3q21 (GATA2 and RPN1). Clinical Details The chromosomal aberrations inv(3)(q21q26.2) and t(3;3)(q21;q26.2) characterize a distinct entity within patients with acute myeloid leukemia (AML). Their incidence in AML is about 1%-2.5% and patients have an unfavorable prognosis and low response to chemotherapy. Inv(3)/t(3;3) juxtapose the GATA2 enhancer with the MECOM locus which results in overexpression of EVI1. The EVI1 gene is located in 3q26 and is involved in hematopoietic stem cell maintenance. EVI1 is together with MDS located in the ´MDS1 and EVI1 complex locus´ (MECOM) and is the major player in this subtype XL t(3;3) GATA2/MECOM DF hybridized to lymphocytes. of AML. Furthermore, structural rearrangements caused by inv(3)/t(3;3) result in One normal interphase and two chromosomes 3 are reduced GATA2 expression which may contribute to the oncogenic potential of this shown. The expected normal signal pattern of XL t(3;3) GATA2/MECOM DF is two orange and two green aberration. GATA2 is located in chromosomal region 3q21 and is involved in develop- signals, representing the two normal MECOM and ment and proliferation of hematopoietic stem cells. Several other recurrent 3q26 G ATA 2 l o c i . B o t h , i n v ( 3 ) ( q 2 1 q 2 6 .
    [Show full text]
  • Ten Commandments for a Good Scientist
    Unravelling the mechanism of differential biological responses induced by food-borne xeno- and phyto-estrogenic compounds Ana María Sotoca Covaleda Wageningen 2010 Thesis committee Thesis supervisors Prof. dr. ir. Ivonne M.C.M. Rietjens Professor of Toxicology Wageningen University Prof. dr. Albertinka J. Murk Personal chair at the sub-department of Toxicology Wageningen University Thesis co-supervisor Dr. ir. Jacques J.M. Vervoort Associate professor at the Laboratory of Biochemistry Wageningen University Other members Prof. dr. Michael R. Muller, Wageningen University Prof. dr. ir. Huub F.J. Savelkoul, Wageningen University Prof. dr. Everardus J. van Zoelen, Radboud University Nijmegen Dr. ir. Toine F.H. Bovee, RIKILT, Wageningen This research was conducted under the auspices of the Graduate School VLAG Unravelling the mechanism of differential biological responses induced by food-borne xeno- and phyto-estrogenic compounds Ana María Sotoca Covaleda Thesis submitted in fulfillment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. dr. M.J. Kropff, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Tuesday 14 September 2010 at 4 p.m. in the Aula Unravelling the mechanism of differential biological responses induced by food-borne xeno- and phyto-estrogenic compounds. Ana María Sotoca Covaleda Thesis Wageningen University, Wageningen, The Netherlands, 2010, With references, and with summary in Dutch. ISBN: 978-90-8585-707-5 “Caminante no hay camino, se hace camino al andar. Al andar se hace camino, y al volver la vista atrás se ve la senda que nunca se ha de volver a pisar” - Antonio Machado – A mi madre.
    [Show full text]
  • Leukaemia Section
    Atlas of Genetics and Cytogenetics in Oncology and Haematology INIST -CNRS OPEN ACCESS JOURNAL Leukaemia Section Short Communication t(3;12)(q26;p13) ETV6/MECOM / t(3;12)(q26;p13) ETV6/EVI1 Etienne De Braekeleer, Nathalie Douet-Guilbert, Marc De Braekeleer Cytogenetics Laboratory, Faculty of Medicine, University of Brest, France (EDB, NDG, MDB) Published in Atlas Database: April 2014 Online updated version : http://AtlasGeneticsOncology.org/Anomalies/t0312.html DOI: 10.4267/2042/54377 This article is an update of : Desangles F. t(3;12)(q26;p13). Atlas Genet Cytogenet Oncol Haematol 1997;1(1):21. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2014 Atlas of Genetics and Cytogenetics in Oncology and Haematology Abstract M7. Short communication on t(3;12)(q26;p13) Epidemiology ETV6/MECOM, with data on clinics, and the genes 46 cases described so far; sex ratio: 29M/16F (1 implicated. unknown); age: 2.5-87 yrs (med: 49 yrs), unknown age for 10 cases. Identity Cytology Note Dysplasia of megakaryocytes, multilineage Only a few cases were shown to involve a involvement. ETV6/MECOM fusion by FISH or RT-PCR. In Prognosis other cases, only MECOM or ETV6 was shown to be rearranged by FISH. Over-expression of See survival curve above. MECOM/EVI1 was found in other cases. Finally, no cytogenetic or molecular analysis was performed Cytogenetics in a few cases. Cytogenetics molecular Heterogeneity of the EVI1 breakpoints, as evidenced by the Cytocell Aquarius EVI1 Breakapart probe. The EVI1 Breakapart probe contains three probes: a probe labeled in Aqua of 562 kb in size centromeric to the EVI1 gene, a probe labeled in Spectrum Green of 181 kb covering EVI1 and its flanking regions and a probe labeled in Spectrum Orange of 124 kb telomeric of the EVI1 gene (telomeric of t(3;12)(q26;p13) G-banding - Courtesy Jean-Luc Lai and Alain Vanderhaegen.Clinics and pathology MYNN and covering LRRC34).
    [Show full text]
  • IGH Rearrangement in Myeloid Neoplasms Sion and Activation
    CASE REPORTS genes such as MYC and BCL2, leading to their overexpres- IGH rearrangement in myeloid neoplasms sion and activation. Here, we found two IGH rearrange- ments in myeloid tumors, including an IGH-MECOM in a Though immunoglobulin genes are typically expressed myelodysplastic syndrome (MDS) and an IGH-CCNG1 in in B lymphocytes, recent studies found ectopic an AML. Our studies provide the first evidence that a once immunoglobulin expression in non-B-cell tumor cells believed B-cell tumor-specific oncogenic mechanism is including acute myeloid leukemia (AML). The also present in myeloid tumors. immunoglobulin genes, including immunoglobulin heavy Case #1: A 60-year-old female with a history of breast chain genes (IGH), light kappa (k) chain genes (IGK) and cancer presented with fatigue, bilateral flank pain, and 9 light lambda (λ) chain genes (IGL), are frequently hematuria. Complete blood count showed 24.82x10 /L of rearranged in B-cell tumors. These rearrangements result white blood cells, 11.2 g/dL of hemoglobin, 33.9% of in a juxtaposition of IG enhancers to the vicinity of onco- hematocrit, and 68x109/L of platelets. The bone marrow A B C D E Figure 1. Acute myeloid leukemia with an IGH-CCNG1 rearrangement. (A) Chromosome analysis of the bone marrow aspirate showed a complex karyotype, including an unbalanced translocation involving chromosomes 5, 14 and 19. Arrows indicate clonal aberrations. (B) Fluorescence in situ hybridization (FISH) on abnormal metaphase showed the 3'IGH (red) remaining on the derivative chromosome 14 and the 5'IGH lost, consistent with an unbalanced IGH rearrange- ment.
    [Show full text]
  • TAZ-CAMTA1 and YAP-TFE3 Alter the TAZ/YAP Transcriptome By
    RESEARCH ARTICLE TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex Nicole Merritt1†, Keith Garcia1,2†, Dushyandi Rajendran3, Zhen-Yuan Lin3, Xiaomeng Zhang4, Katrina A Mitchell4,5, Nicholas Borcherding6, Colleen Fullenkamp1, Michael S Chimenti7, Anne-Claude Gingras3, Kieran F Harvey4,5,8, Munir R Tanas1,2,9,10* 1Department of Pathology, University of Iowa, Iowa City, United States; 2Cancer Biology Graduate Program, University of Iowa, Iowa City, United States; 3Lunenfeld- Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, United States; 4Peter MacCallum Cancer Centre, Melbourne, Australia; 5Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia; 6Department of Pathology and Immunology, Washington University, St. Louis, United States; 7Iowa Institute of Human Genetics, Carver College of Medicine, University of Iowa, Iowa City, United States; 8Department of Anatomy and Developmental Biology and Biomedicine Discovery Institute, Monash University, Clayton, Australia; 9Holden Comprehensive Cancer Center, University of Iowa, Iowa City, United States; 10Pathology and Laboratory Medicine, Veterans Affairs Medical Center, Iowa City, United States *For correspondence: Abstract Epithelioid hemangioendothelioma (EHE) is a vascular sarcoma that metastasizes early [email protected] in its clinical course and lacks an effective medical therapy. The TAZ-CAMTA1 and YAP-TFE3 fusion proteins are chimeric transcription factors and initiating oncogenic drivers of EHE. A combined †These authors contributed proteomic/genetic screen in human cell lines identified YEATS2 and ZZZ3, components of the equally to this work Ada2a-containing histone acetyltransferase (ATAC) complex, as key interactors of both fusion Competing interests: The proteins despite the dissimilarity of the C terminal fusion partners CAMTA1 and TFE3.
    [Show full text]
  • Trim24 Targets Endogenous P53 for Degradation
    Trim24 targets endogenous p53 for degradation Kendra Alltona,b,1, Abhinav K. Jaina,b,1, Hans-Martin Herza, Wen-Wei Tsaia,b, Sung Yun Jungc, Jun Qinc, Andreas Bergmanna, Randy L. Johnsona,b, and Michelle Craig Bartona,b,2 aDepartment of Biochemistry and Molecular Biology, Program in Genes and Development, Graduate School of Biomedical Sciences and bCenter for Stem Cell and Developmental Biology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030; and cDepartment of Molecular and Cellular Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030 Edited by Carol L. Prives, Columbia University, New York, NY, and approved May 15, 2009 (received for review December 23, 2008) Numerous studies focus on the tumor suppressor p53 as a protector regulator of p53 suggests that potential therapeutic targets to of genomic stability, mediator of cell cycle arrest and apoptosis, restore p53 functions remain to be identified. and target of mutation in 50% of all human cancers. The vast majority of information on p53, its protein-interaction partners and Results and Discussion regulation, comes from studies of tumor-derived, cultured cells Creation of a Mouse and Stem Cell Model for p53 Analysis. To where p53 and its regulatory controls may be mutated or dysfunc- facilitate analysis of endogenous p53 in normal cells, we per- tional. To address regulation of endogenous p53 in normal cells, formed gene targeting to create mouse embryonic stem (ES) we created a mouse and stem cell model by knock-in (KI) of a cells and mice (12), which express endogenously regulated p53 tandem-affinity-purification (TAP) epitope at the endogenous protein fused with a C-terminal TAP tag (p53-TAPKI, Fig.
    [Show full text]
  • TP53 Mutations As a Driver of Metastasis Signaling in Advanced Cancer Patients
    cancers Article TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients Ritu Pandey 1,2,*, Nathan Johnson 3, Laurence Cooke 1, Benny Johnson 4, Yuliang Chen 1, Manjari Pandey 5, Jason Chandler 5 and Daruka Mahadevan 6,* 1 Cancer Center, University of Arizona, Tucson, AZ 85724, USA; [email protected] (L.C.); [email protected] (Y.C.) 2 Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ 85724, USA 3 School of Medicine, Vanderbilt University, Nashville, TN 37325, USA; [email protected] 4 MD Anderson Cancer Center, Houston, TX 77030, USA; [email protected] 5 West Cancer Center, 7945 Wolf River Blvd, Germantown, TN 38138, USA; [email protected] (M.P.); [email protected] (J.C.) 6 Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA * Correspondence: [email protected] (R.P.); [email protected] (D.M.) Simple Summary: The DNA sequencing of cancer provides information about specific genetic changes that could help with treatment decisions. Tumors from different tissues change over time and acquire new genetic changes particularly with treatment. Our study analyzed the gene changes of 171 advanced cancer patients. We predicted that tumors gain new mutations but that TP53 mutations (guardian of the human genome) are conserved as the tumor progresses from primary to metastatic sites and across tissue types. We analyzed the primary and metastatic site gene changes in 25 tissue types and conducted in-depth analysis of colon and lung cancer sites for substantial changes. TP53 site specific mutations were different across tissue types and suggest different molecular changes.
    [Show full text]
  • Trim24-Regulated Estrogen Response Is Dependent on Specific Histone Modifications in Breast Cancer Cells
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2012 TRIM24-REGULATED ESTROGEN RESPONSE IS DEPENDENT ON SPECIFIC HISTONE MODIFICATIONS IN BREAST CANCER CELLS Teresa T. Yiu Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Biochemistry Commons, Cancer Biology Commons, Medicine and Health Sciences Commons, and the Molecular Biology Commons Recommended Citation Yiu, Teresa T., "TRIM24-REGULATED ESTROGEN RESPONSE IS DEPENDENT ON SPECIFIC HISTONE MODIFICATIONS IN BREAST CANCER CELLS" (2012). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 313. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/313 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. TRIM24-REGULATED ESTROGEN RESPONSE IS DEPENDENT ON SPECIFIC HISTONE
    [Show full text]